Get the Stockscreener App
1.0019
0.19%
0.0019
Shattuck Labs Inc stock is traded at $1.0019, with a volume of 50,680.
It is up +0.19% in the last 24 hours and up +17.69% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$1.00
Open:
$0.9847
24h Volume:
50,680
Relative Volume:
0.26
Market Cap:
$48.00M
Revenue:
$2.72M
Net Income/Loss:
$-85.08M
P/E Ratio:
-0.5191
EPS:
-1.93
Net Cash Flow:
$-70.93M
1W Performance:
-8.92%
1M Performance:
+17.69%
6M Performance:
-0.31%
1Y Performance:
-86.62%
1-Day Range:
$0.9718
$1.025
1-Week Range:
$0.9718
$1.12
52-Week Range:
$0.6922
$7.6601
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
1.002 | 47.41M | 2.72M | -85.08M | -70.93M | -1.93 |
|
ONC
Beigene Ltd Adr
|
241.99 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.86 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.93 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.00 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Peritoneal Cancer Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Dimensional Fund Advisors LP Sells 109,300 Shares of Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $7.50 Average PT from Brokerages - Defense World
LAWSUITS FILED AGAINST STTK, ASTR and CELHJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Lawsuits Filed Against STTK, EDU and ASTR – Jakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST BMBL, STTK and SPWRJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST STTK, RIVN and AIJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Renaissance Technologies LLC Reduces Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Renaissance Technologies LLC Sells 222,500 Shares of Shattuck Labs, Inc. (NASDAQ:STTK) - The AM Reporter
Shattuck Labs Advances SL-325 Program Amid Financial Progress - TipRanks
LAWSUITS FILED AGAINST FSLR, CLVT and STTKJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Shattuck Labs, Inc. (NASDAQ:STTK) Shares Bought by JPMorgan Chase & Co. - Defense World
Shattuck Labs First Quarter 2025 Earnings: US$0.27 loss per share (vs US$0.37 loss in 1Q 2024) - Yahoo Finance
STTK Prepares for Phase 1 Clinical Trial of SL-325 | STTK Stock News - GuruFocus
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Shattuck Labs Inc (STTK) Reports Q1 2025 EPS of -$0.27, Narrowly Beating Estimates - GuruFocus
Shattuck Labs Reports First Quarter 2025 Financial Results and R - GuruFocus
Shattuck Labs, Inc. SEC 10-Q Report - TradingView
Shattuck Labs Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
STTK STOCK ALERT: Levi & Korsinsky Notifies Shattuck Labs, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Lawsuits Filed Against CHGG, STTK and EDUJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Google Earnings: The One Metric That No One Saw Coming - The Globe and Mail
Shattuck Labs (STTK) to Release Earnings on Thursday - Defense World
HVAC and Water Systems Stocks Q4 In Review: Advanced Drainage (NYSE:WMS) Vs Peers - The Globe and Mail
Shattuck Labs, Inc. (NASDAQ:STTK) Receives $7.50 Average Price Target from Analysts - Defense World
Shattuck Labs at 24th Annual Needham Conference: Strategic IBD Focus By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
3 Promising Penny Stocks With Market Caps Under $300M - simplywall.st
Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference - The Manila Times
24,446 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Virtu Financial LLC - Defense World
Biotech Spotlight: Shattuck Labs CEO Set for Major Investor Presentation at Needham Conference - Stock Titan
STTK stock plunges to 52-week low, touches $0.93 - Investing.com
Brokers Issue Forecasts for Shattuck Labs Q1 Earnings - Defense World
515,619 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Takeda Pharmaceutical Co. Ltd. - MarketBeat
H.C. Wainwright holds Shattuck Labs stock at Neutral - Investing.com
Shattuck Labs Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Shattuck Labs (NASDAQ:STTK) Given Neutral Rating at HC Wainwright - Defense World
Shattuck Labs’ (STTK) “Hold” Rating Reaffirmed at Needham & Company LLC - Defense World
Shattuck Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Shattuck Labs Inc (STTK) Q4 2024 Earnings: EPS of -$0.37 Misses Estimate, Revenue of $0.71M Below Expectations - GuruFocus
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | Director |
Dec 04 '24 |
Sale |
1.25 |
133,371 |
166,714 |
5,406,353 |
17.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):